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Abstract  
Background 
 
Breast cancer is a highly heterogeneous disease. Accurate subtyping or classification of breast 
cancer is important for ensuring proper treatment of patients and also for understanding the 
molecular mechanisms driving the disease. While there have been several gene signatures 
proposed in the literature to classify breast tumours, these signatures show very low overlaps, 
considerably different classification performance, and not much relevance to the underlying 
biology of these tumours.  Here we evaluate DNA-damage response (DDR) and cell-cycle 
pathways, which are critical pathways implicated in a considerable proportion of breast 
tumours, for their usefulness and ability in breast tumour subtyping. We think that subtyping 
breast tumours based on these two pathways could lead to vital insights into molecular 
mechanisms driving these tumours. 
 
Results 
Here, we performed a systematic evaluation of DDR and cell-cycle pathways for subtyping of 
breast tumours into the five known intrinsic subtypes. We observed that the Homologous 
Recombination (HR) pathway showed the best performance in subtyping breast tumours, 
indicating that HR genes are strongly involved in all breast tumours. Comparisons with cell 
cycle pathway and two standard gene signatures showed that DDR pathways still showed the 
best performance, thereby supporting the use of known pathways for breast tumour subtyping. 
Further, the evaluation of these standard gene signatures showed that breast tumour 
subtyping, prognosis and survival estimation are all closely related. Finally, we constructed an 
all-inclusive “super-signature” by combining (union of) all genes and performing a stringent 
feature selection, and found it to be reasonably accurate and robust in classification as well as 
prognostic value. 
 
Conclusions 
Adopting DDR and cell cycle pathways for breast tumour subtyping achieved robust and 
accurate breast tumour subtyping, and constructing a super-signature which contains a “good” 
(feature selected) mix of genes from these molecular pathways as well as clinical aspects (e.g. 
prognosis and survival estimation) is valuable in clinical practice.
 - 3 - 
Background 
 
Tumour cells display a high degree of genomic instability due to the loss of key genes 
responsible for maintaining the integrity of the genome and suppressing unwarranted cell 
division [1]. Due to high proliferation rates and genomic instability, tumour cells tend to have 
different points of genesis and follow different developmental paths, thereby making tumours 
highly diverse. Such diversity in turn makes it difficult for accurate prognosis and 
development of effective therapies. 
Breast cancer displays highly heterogeneous characteristics [2]. With more than one million 
reported cases and a mortality rate of 450,000 per year,  breast cancer is also one of the most 
common cancers worldwide, and in 2012 was the most commonly diagnosed cancer among 
Australian women [3]. This warrants a large-scale study of breast cancer by means of 
systematic stratification and characterization of subtypes and stages in order to develop 
effective therapies. 
Breast cancer subtyping  
It is critical to classify breast cancer into distinct subtypes for both research purposes as well 
as in clinical practice. Clinical subtyping of breast cancer is usually the first step towards 
judging the type, dosage and extent of therapy for treating patients. On the other hand, 
studying and understanding the underlying cellular mechanisms driving breast cancer requires 
a molecular subtyping scheme. While developing a robust subtyping scheme which is relevant 
for research purposes and is also translatable to the clinic has remained a significant 
challenge, there have been several proposed schemes, and most of these are based on the 
expression and mutation of a collection of genes most likely to be involved in the cancer. 
Here, we focus on classification schemes based on the expression of genes to define 
molecular subtypes. 
Comprehensive gene-expression profiling of breast tumours has revealed at least three major 
subtypes, namely luminal (luminal A & B), basal-like or triple-negative, and the human 
epidermal growth factor (EGFR) 2 (HER2)-enriched subtypes (apart from the less commonly 
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accepted normal-type) [2]. Due to morphological and biological differences among breast 
cancer subtypes, different risk factors, disease prognoses and therapeutic responses are 
associated with these subtypes [4]. Luminal tumours usually show better response to 
(hormonal) therapies, and display better prognosis and survival rates. However, triple-
negative tumours are highly aggressive and display worse prognosis, and because they do not 
express any of the three hormone receptors, classical hormonal therapies are not effective in 
treating these tumours [5].  
Gene expression profiling has been extensively used to identify and extract gene signatures 
for cancer classification, diagnosis and prognosis. Several studies have been undertaken to 
identify these signatures under different contexts. However, due to lack of a consensus gene 
signature and thorough understanding of the underlying biological significance of these 
signatures, these studies have not been fully effective to achieve a robust classification [6].   
van't Veer et al. [7] developed a 70-gene signature, also known as Amsterdam 70, which is 
among the most commonly used gene signatures for predicting lymph node negative breast 
tumours from short intervals to distant metastasis. This signature was identified by 
comprehensive gene expression profiling of 117 breast cancer tumours, and was further 
validated on 295 breast cancer patients.  The PAM50 gene signature is another commonly 
used signature for breast cancer prognosis. Developed by Parker et al. using microarray and 
RT-qPCR data generated from 189 breast cancer tumours, a set of 50 genes was selected 
using the Prediction Analysis Microarray (PAM) algorithm [8] and was shown to have a good 
predictive capability.  On the other hand, Pawitan et al. [9] identified a set of 64 genes from 
159 breast cancer patients which gave a robust classification between patients with good and 
poor response to therapies. In another study, Wang et al. [10] developed a 76-gene signature 
by gene expression profiling of 286 lymph node negative breast cancer patients [6]. Several 
other gene signatures have been developed for the same or similar purposes such as the 
intrinsic subtype [11-13], recurrence score [14] and two-gene ratio [15] models. 
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Identifying a standard gene signature for breast cancer classification still remains a challenge. 
Although the current gene signatures track similar biological characteristics such as 
prognosis, response to therapy or survival rates, there is very little overlap among them [6]. 
For instance, the 70 and 76 gene signatures developed by van’t Veer et al. [7] and Wang et al. 
[10] respectively, are both used for distinguishing metastatic from non-metastatic breast 
cancer, but share only 3 genes in common [16].   Studies evaluating these signatures have 
suggested that it is often difficult to understand the underlying biological relevance of these 
signatures mainly because up to 30% of these genes have an unknown function while the rest 
of them are associated with unrelated biological pathways [6]. Furthermore, data over-fitting 
is an inevitable issue while working with high-dimensional data generated from microarray 
studies, causing gene signatures trained on one dataset to become ineffective in classifying 
other (independent) datasets [6].   
Contributions of our work 
For the above reasons, we select well-defined pathways such as DNA damage response 
(DDR) and cell cycle as a means of differentiating breast cancer subtypes. Constructing gene 
signatures using known pathways might be a promising approach to overcome these issues in 
cancer subtyping, particularly understanding the biological significance of the signatures. 
Moreover, using gene signatures with known biological mechanism can lead to mechanistic 
insight into the process of disease and eventually testable hypotheses. In fact in a comparative 
study between different known biological pathways, Liu et al. [6] demonstrated that genes 
involved in cell-cycle pathways could be used as a potential gene signature for breast cancer 
prognosis. While curated pathways are still incomplete and may miss a few genes, recent 
significant efforts in KEGG [17], Reactome [18], BioCarta [http://www. biocarta.com] have 
helped to gather considerable knowledge on key pathways, which when properly adopted 
could help to bridge this gap between gene signatures, cancer subtyping and biological 
relevance of signatures and subtypes. Moreover, several studies [19] have suggested that 
abnormal expression of these genes are associated with DNA damage response in almost all 
the breast cancer subtypes. 
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To maintain genome integrity and prevent damage against mutations caused by internal as 
well as external factors, cells have evolved intricate and robust mechanisms collectively 
known as DNA Damage Response (DDR). Very broadly, these mechanisms follow three 
major steps [1]:  
(i) sensing DNA damage, 
(ii) assembling DNA repair machinery at sites of DNA damage, and 
(iii) repair of damaged DNA. 
The following are the six core pathways in DDR that we consider in our study:  
(i) Base excision repair (BER)   
(ii) Nucleotide excision repair (NER)  
(iii) Homologous recombination (HR)  
(iv) Non-homologous end joining (NHEJ)    
(v) Mismatch repair (MMR)   
(vi) Fanconi anemia (FA) 
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Results  
Data sources  
The breast cancer gene-expression dataset was obtained from The Cancer Genome Atlas 
(https://tcga-data.nci.nih.gov/tcga/) containing 547 samples with the following class labels: 98 
Basal, 58 HER2, 232 Luminal-A, 129 Luminal-B and 30 Normal-like. 
Genes involved in the six different DDR pathways were collated from the public databases 
KEGG [17] and Reactome [18] and an “in-house” database curated from the literature [20]; 
genes involved in these pathways are shown in Table 1. Apart from these, we gathered the 
cell cycle pathway from Liu et al. [6].  Next, we gathered three standard gene signatures from 
the literature, namely Amsterdam-70, PAM-50 and the one from Sotiriou et al. [21], shown in 
Table 2. 
Relative performance of DDR pathways in breast cancer subtyping 
Figure 1 shows the relative performance of the six DDR pathways in classifying breast cancer 
samples into the five class labels (Basal, Luminal-A, Luminal-B, Her2+ and Normal-like) 
using four different clustering algorithms (with number of clusters k = 5) measured by 
adjusted Rand index (ARI) (see Methods). While we can roughly discern from the figure that 
all methods showed their best performance on HR, it is difficult to accurately gauge the 
relative performance of the pathways. Therefore, we used a normalization-based ranking 
scheme [22] to rank the pathways as follows. For each clustering method, we computed the 
ARI for all pathways and normalized these values against the maximum, as shown in Table 3. 
We then summed up these normalized values for each pathway across all clustering methods 
to obtain a total normalized value, which gave the final ranking for all pathways, as shown in 
Table 4. 
Based on Table 4, we could confirm that the double-strand repair HR pathway showed the 
best performance in classifying breast cancer samples. This meant that HR genes showed the 
most differences in terms of their expression values across different subtypes. This can be 
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attributed to the change in expression levels of the two key breast cancer susceptibility genes 
BRCA1 and BRCA2 housed within the HR pathway, between the subtypes, which is likely to 
impact the expression levels of other genes in the same pathway. Also interestingly, all 
pathways showed a normalized value of at least 0.50 (relative to HR), thereby indicating that 
DDR pathways played a considerable role in breast cancer. 
Although Table 4 gives a reasonable overall picture of the performance of different DDR 
pathways, it is difficult to judge whether the lower performance of a pathway (e.g. NHEJ with 
normalized value 0.569 relative to HR) indicated lower involvement of this pathway in breast 
cancer or it was involved in only a subset (and not all) of the subtypes. Therefore, we 
evaluated the capability of DDR pathways for pair wise classification of breast cancer 
subtypes to understand the extent of involvement of each of these pathways in different 
subtypes. 
Relative performance of pathways in pair-wise classification of breast cancer samples 
At a time we only considered samples from a pair of subtypes, and evaluated the performance 
of each pathway in classifying these samples into the two classes. Figure 2 shows the ARI for 
different clustering methods (number of clusters k = 2; see Methods) when used to classify 
samples in this pair-wise manner.  
From the figure we note the performance on Basal vs Normal-like and Her2+ vs Normal-like 
strikingly stand out for all pathways. In other words, all pathways are able to differentiate 
Basal-like from Normal-like and Her2+ from Normal-like with high accuracy. Two 
observations can be inferred here (although both observations are related to each other): (i) all 
pathways show considerable differences in the expression levels of their genes between the 
two subtypes; and (ii) the two tumour subtypes are considerably different from the one 
another, that is, Basal-like is very different from Normal-like, and Her2+ is very different 
from Normal-like. This is not entirely surprising because Basal-like is a highly aggressive 
subtype characterized by worst prognosis and low survival rates, while Normal-like is far less 
aggressive [2,4,5]. Similarly, Her2 is also aggressive, and therefore different from the less 
aggressive Normal-like subtype [23]. From the figure, we also see that Basal-like vs Her2+ 
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also showed considerable differences across all pathways. Basal-like is predominantly triple 
negative, that is, does not express the hormones ER/PR/Her2, while the Her2+ type expresses 
HER2. Her2+ subtype can be treated using hormonal therapy including Trastuzumab  and 
Lapatinib [24], while for triple-negative subtypes hormonal therapies are not effective [5]. 
Therefore, although both are highly aggressive, these two subtypes are considerably different 
from one another in terms of molecular characteristics. 
Next, Figure 3 shows plots for relative ranking of different pathways in the pair-wise 
classification of subtypes (using the normalized ranking procedure as before). While all 
pathways show highest classification capability between Basal-like vs Normal-like, and Her2 
vs Normal-like (as noted before), while we go down the ranks, the pathways show 
classification capability in separating different subtype pairs. For example, the HR and FA 
pathways can differentiate Basal from Luminal-A better than the remaining pathways. On the 
other hand, NER can differentiate between Basal and Luminal-B better than the remaining 
pathways. These observations mean that genes in HR and FA pathways show more 
differences in their expression levels between Basal and Luminal-A compared to the genes in 
other pathways. In other words, HR and FA genes are likely to be more responsible for the 
inherent differences between Basal and Luminal-A subtypes. Similarly, NER genes are more 
responsible for the inherent differences between Basal and Luminal-B subtypes.  
Going back to Figure 1, we see that the ARI of all DDR pathways ranged roughly between 
0.20 and 0.40. Therefore, none of the pathways were able to completely differentiate breast 
cancer samples into all five subtypes with high accuracy (ARI  0.50). This indicated that 
DDR genes alone are not sufficient to clearly draw the lines between the subtypes and 
possibly genes from other processes (e.g. cell cycle) need to be included to obtain a more 
accurate classification. Therefore, we next repeated our experiments by including cell cycle 
pathway as well as the different gene signatures into our evaluation. 
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Relative performance of DDR and cell cycle pathways and gene signatures 
To evaluate the performance of DDR as a whole against other pathways and signatures, we 
combined all the genes from the six DDR pathways. Figure 4 shows the performance of DDR, 
cell cycle and the three gene signatures, Amsterdam-70, PAM50 and Sotiriou et al. in 
classifying breast tumours. It is not surprising to see that PAM50 showed the best 
performance, which is because PAM50 genes were used as part of the procedure to generate 
the original class labels in TCGA. However, PAM50 does not give 100% accuracy, which can 
be attributed to the differences between clustering/classification and other post-processing 
methods adopted by the TCGA consortium, which we do not adopt here. 
Figure 4 shows the overall ranking for these pathways and signatures. Interestingly, DDR 
genes are ranked second (after PAM50) followed by cell cycle and the two gene signatures. 
This certainly indicates that DDR genes indeed play a crucial role in breast cancer.  
Having said that, we note the two gene signatures, Amsterdam-70 and Sotiriou et al., are not 
primarily designed for subtyping breast tumours into the five intrinsic subtypes, but instead 
for prognosis and survival analysis, and yet show reasonably good performance ( 0.60). 
Further, the Sotiriou et al. [21] signature is primarily for classifying breast tumours based on 
grades. In their work, Sotiriou et al. show that a considerable proportion of grade 1 (low 
grade) breast tumours are ER+, while a considerable proportion of grade 3 (high grade) breast 
tumours are ER-, and we note that ER+ tumours are predominantly luminal while ER- 
tumours are predominantly triple-negative or basal-like [23]. These observations mean that 
breast tumour subtyping, estimation of aggressiveness and prognosis/survival analyses are 
closely related. In other words, if we can accurately classify breast tumours, we will also be 
able to considerably predict the aggressiveness of the tumour and also patient survival. 
Constructing a super-signature 
One limitation often raised in the literature regarding gene signatures is the relatively low 
overlaps among them [6]. When we overlapped the genes from our pathways and signatures, 
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we too observed the same phenomenon (Figure 5). This makes it challenging to obtain an 
“all-inclusive” signature which is both robust and accurate. 
To understand this phenomenon better, we combined the genes from DDR, cell cycle and 
gene signatures to construct an “all-inclusive” signature containing 381 genes. We then 
calculated the ARI for this all-inclusive signature using our four clustering methods. While 
we had expected considerably low ARI due to the inclusion of significant “noise” in this 
super-signature, to our surprise we saw that the ARI was not very low (around 0.40) 
compared to the treating the pathways and signatures separately  (Figures 1 and 6). Also, all 
the methods displayed roughly the same ARI, that is, the methods did not show considerable 
variance as they showed with individual pathways and signatures. Further, performing a 
stringent feature selection [25] (Table 6) we arrived at set of 17 genes, which we call the 
“super-signature”, which did not decrease the performance of these methods considerably 
(Figure 6). Interestingly, some of these genes (Table 6) also showed significant prognostic 
value in terms of patient survival (Figure 7). 
These observations instruct developing a super-signature by selecting a “good” (feature 
selected) mix of genes from relevant molecular pathways (DDR and cell cycle) and clinical 
aspects (prognosis and survival estimation), which is both robust and accurate in research as 
well as clinical practice. 
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Discussion 
Here, we are dealing with a classification problem namely of classifying the samples based on 
the breast tumor subtype labels. However, we use clustering algorithms for this purpose by 
semi-supervising them, that is, by setting the number of clusters to be predicted (k = 2 or k = 
5). This leaves room (our future work) to test these algorithms using pathways and signatures 
for unsupervised classification and thereby possibly identifying novel subtypes. 
Conclusions  
Breast cancer displays highly heterogeneous characteristics [2]. Accurate subtyping or 
classification of breast cancer is therefore crucial in both clinical practice as well as for 
research purposes. While there have been several signatures proposed in the literature to 
classify breast tumours, these signatures show very low overlaps, considerably different 
performance, and not much relevance to the underlying biology of these tumours [6].  On the 
other hand, we note that DDR and cell cycle pathways are significantly involved in all or 
most breast tumours, and therefore these pathways are valuable for breast tumour subtyping. 
Further, being curated based on biological properties, these pathways provide a better 
understanding of the underlying mechanisms of these tumours.  
Here, we performed a systematic evaluation of DDR and cell cycle pathways, and also 
compared their performance against standard gene signatures. We observed that DDR 
pathways showed the best performance in classifying breast tumours into the known five 
intrinsic subtypes, thereby strongly indicating that DDR genes are considerably involved in 
these tumours. In particular, we noted that the HR pathway plays a key role in all breast 
tumours. Further, the evaluation of standard gene signatures, which are primarily developed 
for prognosis and survival estimation, also showed reasonably good performance, further 
indicating that breast tumour subtyping, prognosis and survival estimation are all closely 
related. Finally, we attempted to develop a “super-signature” by combining all the genes and 
performing a stringent feature selection, and to our surprise found it reasonably accurate as 
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well as robust across multiple clustering methods and also significant in terms of prognostic 
value. This hints at developing such a super-signature which contains a “good” mix of genes 
from different pathways (DDR and cell cycle) and clinical aspects (prognosis and survival 
analysis), and which can be both used for molecular subtyping and also in clinical practice. 
 
Methods 
 
Computational analyses including visualization were coded in a pipeline using open source 
libraries in Python programming language. Prior to clustering and data analysis, each input 
file was normalized and rescaled using z-score (mean = 0 and standard deviation = 1).  
Clustering methods namely K-means, average linkage, ward clustering [26] and Hopfield 
network [27] were applied on the datasets. Pycluster library [28] was used for k-means, 
average linkage and ward methods. However, Hopfield network was built, trained and utilized 
from scratch in Python. In each of these clustering methods, we pre-fix the number of clusters 
k to enable classification. 
Scikit-learn library [29] was used for computing the adjusted rand index (ARI). To check 
which gene signatures are giving the best clustering performance, ARI was then normalized 
and ranked [22]. The flow diagram of the computational analysis is available in the 
supplementary website. 
And extended version of this work is published as [31].
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Figures 
Figure 1: Comparison of DDR pathways clustering performance 
Comparison of DDR pathways capabilities in clustering of breast cancer dataset into 5 
subtypes 
 
 
Figure 2: DDR pathways clustering performance: a pairwise comparison 
a) HR, b) NER, c) BER, d) MMR, e) NHEJ, f) FA 
 
 
Figure 3: Overall rank of DDR pathways in terms of pairwise clustering of 
breast cancer subtypes 
Based on normalized total Adjusted Rand Index 
 
Figure 4: Comparison of clustering performance of gene signatures and 
pathways 
 
Figure 5 – Overlaps between pathways and gene signatures 
The pathways and gene signature showed very low overlaps, as also noted in earlier 
studies [6]. 
 
Figure 6 – Performance of a “super-signature” constructed from pathways and 
two standard gene signatures 
(a) Using all genes (381) 
(b) After stringent feature selection (17) 
 
Figure 7 – Prognostic value for genes in the “super-signature” 
Kaplan-Meier plots [30] drawn using the online tool KM-Plotter 
[http://kmplot.com/analysis/] using number of patients n = 2878 for (a) MYB, (b) 
CKS1B and (c) BUB1 
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Tables 
Table 1- List of genes involve in DDR pathways. 
 
Pathway Genes 
BER APEX1, FEN1, LIG1, LIG3, MBD4, MPG, MUTYH, NEIL1, NEIL2, NEIL3, NTHL1, OGG1, 
PCNA, POLB, POLD1, POLD2, POLD3, POLD4, POLE, POLE2,POLE3, POLE4, SMUG1, 
TDG, UNG, XRCC1, PARP1 
NER CCNH, CDK7, CETN2, DDB1, DDB2, EP300, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, 
ERCC6, ERCC8, GTF2H1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, HMGN1, LIG1, LIG3, 
MNAT1, PCNA, POLD1, POLD2, POLD3, POLD4, POLE, POLE2, POLE3, POLE4, POLK, 
POLR2A, POLR2B, POLR2C, POLR2D, POLR2E, POLR2F, POLR2G, POLR2H, POLR2I, 
POLR2J, POLR2J2, POLR2J2, POLR2K, POLR2L, POLR2M, RAD23B, RFC1, RFC2, RFC3, 
RFC4, RFC5, RPA1, RPA2, RPA3, RPA4, TCEA1, TCEA2, TCEA3, XAB2, XPA, XPC 
HR ATM, ATRX, BARD1, BLM, BRCA1, BRCA2, BRCC3, BRE, BTBD12, C12orf48, C16orf75, 
C19orf62, CCDC98, CHD4, cPIAS1, CSNK2A1, CSNK2A1P, CSNK2A2, CSNK2B, DNA2L, 
EME1, ERCC1, ERCC4, EXO1, FLJ40869, H2AFX, HERC2, HTATIP, LIG3, MDC1, 
MRE11A, MUS81, NBN, OBFC2A, OBFC2B, OTUB1, PALB2, PIAS4, POLD1, POLD2, 
POLD3, POLD4, POLH, RAD50, RAD51, RAD51AP1, RAD51C, RAD51L1, RAD51L3, 
RAD52, RAD54B, RBBP8, RBMX, RMI1, RNF168, RNF20, RNF40, RNF8, RTEL1, SHFM1, 
SLX1A, SLX1B, TOP3A, TOP3B, TP53BP1, TRIP12, UBE2N, UBR5, UIMC1, USP3, 
XRCC2, XRCC3, PIAS1, RAD51B, RAD51D, RAD54L, RAD54L2, RPA1, RPA2, RPA3, 
RPA4, SLX4 
MMR EXO1, LIG1, MLH1, MSH2, MSH3, MSH6, PCNA, PMS2, POLD1, POLD2, POLD3, POLD4, 
RFC1, RFC2, RFC3, RFC4, RFC5, RPA1, RPA2, RPA3, RPA4 
NHEJ DCLRE1C, LIG3, LIG4, MRE11A, NBN, NHEJ1, PARP1, PRKDC, RAD50, TP53BP1, 
XRCC1, XRCC4, XRCC5, XRCC6, RBBP8 
FA APITD1, BRCA1, BRCA2, BRIP1, C17orf70, C19orf40, EME1, ERCC1, ERCC4, FAN1, 
FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, 
MAD2L2,MUS81, PALB2, PCNA, RAD51C, REV1, REV3L, SLX4, STRA13, USP1, WDR48 
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Table 2- Gene signatures involve in breast cancer classification used in this study. 
 
Gene signatures 
& pathways 
Study summary # of genes Reference 
Amsterdam70 
Demonstrates a 70 gene 
expression signature that has a 
powerful classification capability 
in 295 breast cancer patients.  
70 Veer et al.[2 in 101] 
PAM50 
Developed a 50 gene subtype 
predictor using microarray and 
RT-qPCR studies of 189 breast 
tumour samples indicating good 
predicting powers in node 
negative breast cancers. 
50 Parker J.S. et al.[113] 
Sotiriou et al. 
In a study of 189 invasive breast 
carcinomas, it was demonstrated 
that this signatures may improve 
accuracy of tumour grading and 
eventually prognosis.  
97 Sotiriou et al.[103] 
Cell cycle 
pathway 
Genes involve in cell cycle were 
shown to have good predictive 
capabilities as compare with 
other gene signatures and 
pathways, using different breast 
cancer datasets. 
25 Liu J. et al.[101] 
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Table 3- Relative ranking of DDR pathways clustering capabilities the basis of ARI. 
Relative ranking of DDR pathways clustering capabilities the basis of ARI 
Method Pathways RI Norm 
Kmeans HR 0.303 1 
 
NER 0.276 0.911 
 
BER 0.247 0.813 
 
FA 0.234 0.773 
 
MMR 0.221 0.727 
 
NHEJ 0.161 0.530 
    
Average link HR 0.276 1 
 
MMR 0.271 0.984 
 
BER 0.229 0.830 
 
FA 0.224 0.812 
 
NER 0.221 0.802 
 
NHEJ 0.087 0.315 
    
Ward HR 0.307 1 
 
MMR 0.243 0.792 
 
NER 0.236 0.770 
 
BER 0.193 0.628 
 
NHEJ 0.187 0.609 
 
FA 0.180 0.586 
    
Hopfield HR 0.207 1 
 
NER 0.206 0.998 
 
BER 0.204 0.985 
 
NHEJ 0.171 0.826 
 
FA 0.162 0.785 
 
MMR 0.129 0.622 
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Table 4- Gene signatures involve in breast cancer classification used in this 
study. 
Overall relative ranking of DDR pathways clustering capabilities on the basis of ARI 
 
 
Pathway Total Norm 
HR 4 1 
NER 3.480 0.870 
BER 3.256 0.814 
MMR 3.125 0.781 
FA 2.956 0.739 
NHEJ 2.279 0.570 
 
 
 
Table 5- Gene signatures involve in breast cancer classification used in this 
study. 
Overall relative ranking of gene signatures clustering capabilities on the basis of ARI 
 
Signature Total Norm 
PAM50 3.859 1 
DDR 3.128 0.810 
Cell Cycle 3.055 0.792 
Sotiriou 2.534 0.657 
Amsterdam70 2.501 0.648 
 
 
Table 6- A feature-selected set of genes in the “super-signature” 
List of genes acquired from after feature selection including all gene signatures and 
pathways in this study: 
 
 
BUB1, FOXA1, ESR1, WISP1, ERBB2, SLC39A6, CDKN2C, SFRP1, MYBL2, RNF40, KRT5, 
E2F3, CDC45L, CKS1B, REV1, FGFR4, PGR 
 
